Direct oral anticoagulants good value for stroke prevention in AF
- PDF / 167,190 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 50 Downloads / 217 Views
1
Direct oral anticoagulants good value for stroke prevention in AF Prescribing patterns for oral anticoagulation in patients with atrial fibrillation (AF) have changed over recent years in England, with rising costs due to increasing use of direct oral anticoagulants (DOACs), but the decline in AF-related stroke resulted in incremental savings at the national level. These are the main findings of a study that examined the changes in the number of oral anticoagulation prescriptions (warfarin or DOACs) and the incidence of hospitalised AF-related stroke in England, comparing the periods January 2011 to June 2014 and July 2014 to December 2017. The budget impacts of these changes were also assessed. The number of oral anticoagulant items prescribed for patients with AF increased significantly over the study period (from median 73 368 for 2011–2014 to 104 680 for 2014–2017; values adjusted for annual AF prevalence). In particular, the number of DOAC items prescribed increased substantially (by 2004.8%), whereas little change was seen in the number of warfarin prescriptions. The associated overall budget impact of the changes in the numbers of oral anticoagulant prescriptions and international normalised ratio (INR) monitoring was estimated at £733 466 204. However, when the 11.3% reduction in the incidence of AF-related stroke was considered, the incremental overall cost of care per patient fell from £1129 in 2011–2014 to £840 in 2014–2017, leading to an incremental £289 saving per patient at the national level. "This analysis supports the use of DOACs for stroke in real-world clinical practice," suggest the researchers. Orlowski A, et al. Clinical and budget impacts of changes in oral anticoagulation prescribing for atrial fibrillation. Heart : 28 Oct 2020. Available from: URL: http:// doi.org/10.1136/heartjnl-2020-317006
1173-5503/20/0866-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
803515276
PharmacoEconomics & Outcomes News 14 Nov 2020 No. 866
Data Loading...
